First reported late last year, Sense Biodetection has confirmed a $50m series B round backed by Cambridge Innovation Capital.

Sense Biodetection, a UK-based molecular diagnostics technology developer, has secured $50m in series B funding from investors including Cambridge Innovation Capital (CIC).

Koch Disruptive Technologies (KDT), a subsidiary of chemicals and industrial group Koch Industries, led the round, which was first rumoured in November 2020.

The round also featured Earlybird Health Tech Fund, a fund managed by venture capital firm Earlybird, as well as Mercia Asset Management and private investor Jonathan Milner.

Sense Biodetection is developing handheld molecular diagnostics tests for the detection of viral and bacterial diseases, and its Veros platform can provide test results in minutes without the use of other instruments.

The funding will support the commercialisation of the company’s covid-19 test as well as development activities for its other molecular testing products.

Harry Lamble, chief executive of Sense, said: “Partnering with KDT provides us the support we need to deliver on our ambitious plans to…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?